Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.

Schmainda, Kathleen M; Prah, Melissa A; Marques, Helga; Kim, Eunhee; Barboriak, Daniel P; Boxerman, Jerrold L

Schmainda, Kathleen M; Prah, Melissa A; Marques, Helga; Kim, Eunhee; Barboriak, Daniel P; Boxerman, Jerrold L.

Affiliation

Schmainda KM; Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Prah MA; Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Marques H; Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Kim E; Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Barboriak DP; Merck Research Laboratories, Kenilworth, New Jersey.
Boxerman JL; Duke University Medical Center, Durham, North Carolina.

Neuro Oncol ; 23(2): 314-323, 2021 02 25.

Article in En | MEDLINE | ID: mdl-32678438

Subject(s)

Brain Neoplasms; Glioblastoma; Bevacizumab/therapeutic use; Brain Neoplasms/diagnostic imaging; Brain Neoplasms/drug therapy; Contrast Media; Glioblastoma/diagnostic imaging; Glioblastoma/drug therapy; Humans; Magnetic Resonance Imaging; Perfusion

Key words

Ktrans; bevacizumab; brain tumor; clinical trial; rCBV

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Glioblastoma Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Neuro Oncol Journal subject: NEOPLASIAS / NEUROLOGIA Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google